Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulforafan alfadex - Evgen

Drug Profile

Sulforafan alfadex - Evgen

Alternative Names: Broccoli-sprout-extract; SFX-01; Stabilised sulforaphane; Sulforadex; Sulforafan-alpha-cyclodextrin; Sulforaphane; Sulforaphane-alpha-cyclodextrin; Sulphoraphane-alfadex

Latest Information Update: 20 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lalilab
  • Developer Evgen Pharma
  • Class Antihaemorrhagics; Antineoplastics; Chemopreventatives; Phytotherapies
  • Mechanism of Action Androgen receptor antagonists; Hedgehog protein modulators; Histone deacetylase inhibitors; NF E2 related factor 2 stimulants; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Subarachnoid haemorrhage
  • Preclinical Multiple sclerosis
  • No development reported Cardiovascular disorders; Chronic obstructive pulmonary disease; Leukaemia

Most Recent Events

  • 13 Feb 2020 The University of Rochester School of Medicine and Dentistry and Evgen Pharma plan a clinical trial for Renal failure in USA
  • 05 Dec 2019 Evgen and University of Dundee enters into a Memorandum of Understanding for clinical trial of Sulforafan alfadex for Non-alcoholic steatohepatitis and Liver fibrosis
  • 05 Dec 2019 Evgen plans a clinical trial for Non-alcoholic steatohepatitis
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AskTheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top